CAS: 7631-94-9; Sodium Dithionate

专利信息

专利号:WO-2023166160-A1
优先权日:2022-03-04
标 题:Process for synthesis of 1,4-dihydronicotinamide riboside (nrh) from nicotinamide-beta-riboside triacetate chloride (nra-cl)
发明人：MALKANNAGARI RAMANI; GUNDAPUNENI RAGHAVA RAO; BOHAN FRODE
权利人:BOHAN & CO AS
摘要:The present invention disclose novel process for synthesis of 1,4- dihydronicotinamide riboside (NRH). More particularly, the invention discloses a cost-effective synthesis of 1, 4-dihydronicotinamide riboside (NRH) from Nicotinamide-beta-riboside triacetate chloride (NRA-CI) in good yields and purity comprising the steps of a) reducing Nicotinamide-beta-riboside triacetate chloride (NRA-CI) in presence of non-chlorinated aprotic organic solvent and a reducing agent to obtain 1,4-dihydronicotinamide riboside triacetate (NRH-A); and b) deacetylating the 1,4-dihydronicotinamide riboside triacetate (NRHA) in presence of a base to obtain 1,4-dihydronicotinamide riboside(NRH)

专利号:US-6455680-B1
优先权日:2000-12-21
标 题 :Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
发明人：LUKIN KIRILL A
权利人:ABBOTT LAB
摘要:An efficient deoximation technique for use in synthesis of erythromycin derivatives, involving aryl thioimine intermediates is disclosed. The aryl thioimine intermediates can be utilized in a method for protecting a ketone of a ketone-containing erythromycin derivative as a thioimine; a method for deoximating an oxime-containing erythromycin derivative, or a method for preparing a 6-O-alkyl erythromycin derivative. Presently preferred erythromycin derivatives have a C-9 oxime or a C-9 ketone.

专利号:US-5338865-A
优先权日:1992-03-12
标 题 :Synthesis of halichondrin B and norhalichondrin B
发明人：KISHI YOSHITO; FANG FRANCIS; FORSYTH CRAIG J; SCOLA PAULA M; YOON SUK KYOON
权利人:HARVARD COLLEGE
摘要:Novel chemical compounds that can be used to synthesize halichondrin B and norhalichondrin B, and related derivatives, are described. The synthesis of halichondrin B and norhalichondrin B from these compounds also is described.

专利号:US-10047065-B2
优先权日:2014-12-17
标 题 :Formation of chromanes based on intermolecular reaction of alkynes with dimethylfuran in the presence of gold(I) complexes
发明人：LETINOIS ULLA; NETSCHER THOMAS
权利人:DSM IP ASSETS BV
摘要:The present invention relates to a method of preparing chromanes from 2,5-dimethylfuran and substituted alkynes comprising an long chain unsaturated alkyl group as substituent in the alpha position of a substituted phenol followed by oxidation, reduction and acid ring closure. It is particularly advantageous to use 2,5-dimethylfuran as this offers an ecological beneficial synthesis of β-tocopherol.

专利号:US-9440948-B2
优先权日:2010-09-03
标题:Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
发明人：KEM WILLIAM READE; SOTI FERENC; ROUCHAUD ANNE; XING HONG; LINDSTROM JON; ANDRUD KRISTIN MARIE
权利人:KEM WILLIAM READE; SOTI FERENC; ROUCHAUD ANNE; XING HONG; LINDSTROM JON; ANDRUD KRISTIN MARIE; UNIV FLORIDA; UNIV PENNSYLVANIA
摘要:Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2′substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2 , compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2′substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.

专利号:US-11359004-B2
优先权日:2012-04-03
标 题:Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
发明人：VANDEGRIFF KIM D; MALAVALLI ASHOK; MKRTCHYAN GNEL
权利人:SCHINDLER WILLIAM
摘要:The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.